Comparison of the prognostic effect of pyrotinib plus trastuzumab and chemotherapy different lines therapy in HER2-positive advanced breast cancer
This study aimed to compare the efficacy of pyrotinib, trastuzumab combined with chemotherapy with different lines therapy in human epidermal growth factor receptor 2- (HER2-) positive advanced breast cancer (ABC) and analyze the factors affecting the prognosis. A total of 84 patients with median age of 49 year-old. The mPFS of patients receiving first-line pyrotinib plus trastuzumab and chemotherapy was the longest (11 months) compared with second- and third line patients (p = 0.106). The objective response rate (ORR) and disease control rate (DCR) of the total population were 33.3% and 82.1% respectively. Subgroup analys...
Source: Journal of Chemotherapy - April 1, 2024 Category: Cancer & Oncology Authors: Yangqingqing Zhou Hui Wang Jiao Yang Fan Wang Danfeng Dong Xiaoai Zhao Le Wang Ruiyuan He Zhiping Ruan Jin Yang Source Type: research
